RIPK1 and systemic inflammatory response syndrome: Wang et al. reported an oleanolic acid base necroptosis inhibitor CDDO and its analogs prevented necrosome formation by targeting Hsp90 to inhibit RIPK1 and RIPK3 phosphorylation in necroptotic cells, and reduced TNF-induced SIRS as well as cerebral I/R injury in vivo [156].